LEADER 01599oas  2200529 a 450 
001 9910695716603321
005 20070425151719.0
035   $a(CKB)5470000002372618
035   $a(OCoLC)44167594$z(OCoLC)44288997$z(OCoLC)51268523
035   $a(EXLCZ)995470000002372618
100   $a19981016b199u2004  sa              
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNIAID Council news$b[electronic resource]
210   $a[Bethesda, Md.] $c[National Institute of Allergy and Infectious Diseases]$d[-2004]
300   $aDescription based on: Jan. 10, 2000; title from contents screen (publisher Web site, viewed May 12, 2006).
517 3 $aCouncil news
517 1 $aNewsletter, NIAID research funding
606   $aFinancing, Government
606   $aResearch Support as Topic
606   $aTraining Support
606   $aCommunicable Diseases
606   $aHypersensitivity
607   $aUnited States
608   $aPeriodical.
615 12$aFinancing, Government.
615 22$aResearch Support as Topic.
615 22$aTraining Support.
615 22$aCommunicable Diseases.
615 22$aHypersensitivity.
712 02$aNational Institute of Allergy and Infectious Diseases (U.S.)
801  0$bNLM
801  1$bNLM
801  2$bOCL
801  2$bOCLCQ
801  2$bOCL
801  2$bNLM
801  2$bAAA
801  2$bOCLCQ
801  2$bGPO
906   $aDOCUMENT
912   $a9910695716603321
996   $aNIAID Council news$93094334
997   $aUNINA